alx-0600 and pasireotide

Dumping syndrome is a common and debilitating complication of upper gastrointestinal surgery. Accelerated gastric emptying and dysregulated secretion of gastrointestinal (GI) hormones are involved in its pathophysiology. Pasireotide, a novel somatostatin analogue, improved dumping in a phase-2 study. Preliminary data suggest that the glucagon-like peptide-1 (GLP-1) analogue liraglutide can also improve dumping. Short bowel syndrome is the most common cause of intestinal failure and involves not only a loss of mucosal absorptive area but also hypersecretion and accelerated transit. GLP-2 is the best studied hormone involved in intestinal adaptation. An increasing body of evidence demonstrates that the GLP-2 analogue teduglutide reduces parenteral support needs. New GLP-2 analogues and analogues of other GI hormones such as liraglutide are being investigated as promising treatments in short bowel syndrome.

Topics: Animals; Dumping Syndrome; Gastrointestinal Agents; Gastrointestinal Motility; Gastrointestinal Tract; Humans; Intestinal Absorption; Ligands; Liraglutide; Peptides; Receptors, Gastrointestinal Hormone; Short Bowel Syndrome; Signal Transduction; Somatostatin; Treatment Outcome

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Approval; Drug Therapy; Fibrinolysin; Heterocyclic Compounds, 3-Ring; Humans; Oxazines; Peptide Fragments; Peptides; Piperazines; Pyridones; Simeprevir; Sofosbuvir; Somatostatin; Sulfonamides; Uridine Monophosphate